



Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease

Kajja-Leena Kolho^{1,2*}

¹ Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ² Faculty of Medicine and Medical Technology, Tampere University, Tampere, Finland

OPEN ACCESS

Edited by:

Eytan Wine,
University of Alberta, Canada

Reviewed by:

Eleftheria Stamatios Roma,
University of Athens, Greece
Vaidotas Urbonas,
Vilnius University Children's
Hospital, Lithuania

*Correspondence:

Kajja-Leena Kolho
kajja-leena.kolho@helsinki.fi

Specialty section:

This article was submitted to
Pediatric Gastroenterology,
Hepatology and Nutrition,
a section of the journal
Frontiers in Pediatrics

Received: 30 October 2020

Accepted: 15 December 2020

Published: 13 January 2021

Citation:

Kolho K-L (2021) Therapeutic Drug
Monitoring and Outcome of Infliximab
Therapy in Pediatric Onset
Inflammatory Bowel Disease.
Front. Pediatr. 8:623689.
doi: 10.3389/fped.2020.623689

Inflammatory bowel disease (IBD) with pediatric onset has become more prevalent during past decades. Thus, the number of patients with moderate to severe disease subtype treated with antagonists to tumor necrosis factor alpha (TNF α) has concurrently risen. Most pediatric patients initially respond to these drugs but will need dose escalation during the first year of therapy. As pediatric data regarding therapeutic drug monitoring during therapy with TNF α -blocker adalimumab are sparse, this review focuses on the literature on therapeutic drug monitoring of infliximab and how it may guide management.

Keywords: anti-TNF, children, Crohn disease, ulcerative colitis, unclassified colitis

INTRODUCTION

Infliximab, which is a monoclonal antibody to tumor necrosis factor alpha (TNF α), has become the mainstay therapeutic agent for treating moderate to severe pediatric inflammatory bowel disease (PIBD). This is comparable with the management of adult IBD. The patent for infliximab expired in Europe in 2015 and nowadays there are on the market several biosimilars to the original drug Remicade (Janssen Biologics) (1, 2). So far, there are no safety alarms related to the use of biosimilars and the efficacy in clinical practice is comparable to the original drug (2). The access to the different drugs and their use varies between countries. Infliximab and its biosimilars are licensed for use in children who are at least 6 years of age and have moderate to severe Crohn disease or ulcerative colitis. Several countries, such as Finland, allow off-label use in younger children at the physicians' discretion. Induction phase of the drug covers 8 weeks and the three first doses are administered intravenously at week 0, 2, and 6, and mostly as 5 mg/kg. Maintenance phase and the fourth dose follow after 8 weeks (1–5). Most patients with PIBD, especially with Crohn disease, initially respond to infliximab therapy but will need dose escalation during the first year of therapy (6–8). This includes shortening of the interval and increasing the dose. To guide therapeutic decisions, the use of trough level measurements of infliximab have emerged (9–12). In PIBD, the published reports on drug level monitoring mostly concern the use of the original drug and the use of biosimilars is less addressed. This review discusses use of infliximab trough level measurements in the management of PIBD.

Why Do Patients With Pediatric Onset Inflammatory Bowel Disease Treated With Infliximab Need Trough Level Measurements of the Drug?

Induction of infliximab therapy results in responders in rapid improvement of clinical symptoms, blood and fecal inflammatory markers (13, 14), and even weight gain (15, 16). For example, the normalization of fecal calprotectin levels may occur already during the first 2 weeks of the therapy when response is complete (17). Perhaps unexpectedly, in partial responders the improvement in the objective markers of inflammation is only modest between therapy weeks 2 and 6 (17–19). During the first year of therapy up to 80% of the pediatric patients may need therapy escalation and one third may eventually be judged as non-responders and need switching to other therapeutic drugs (6–8, 20). When non-response is timely detected and therapy adjusted accordingly, the therapeutic drug monitoring improves cost-effectiveness of the management (21, 22).

Most reports on infliximab trough levels in PIBD originate from single centers and are retrospective reports. Therefore, the number of included patients is limited, the timing of trough level measurements is variable, and in most studies, only samples taken during maintenance therapy are included. **Table 1** summarizes some of the most recent studies with considerable number of patients with PIBD (23–31). The general conclusion from these studies is that in the group of patients with clinical remission or mild disease activity, the trough levels of infliximab are statistically significantly higher than in the group of patients with poor or unsatisfactory response. Also, the proportions of patients with undetectable or low levels of the drug are higher in the latter groups. However, the absolute values of the median (or mean) values are close to one another and there is significant overlap with the interquartile ranges of the values. In current clinical practice the target range is somewhat higher than in the early days of adopting the infliximab therapy in PIBD. There is no clear consensus of the target trough levels but levels above 3–5 mg/mL are considered adequate (11). This applies to all disease subtypes, i.e., Crohn disease, ulcerative colitis and unclassified colitis (31–33). However, in acute severe colitis to reach these levels may need vigorous dosing probably due to increased clearance of the drug in active inflammation (3, 5). Notably, in perianal fistulizing disease the target level for best prediction of fistula healing may be as high as 12.7 mg/mL (34). Importantly, higher trough levels do not result in increased risk for infections or other adverse events (35). It is remarked that there is variability in the performance of the different assays for measurement of the drug levels hampering the comparison of absolute values in different settings (36). There are less data on the performance of the commercial assays when using biosimilars but according to our experience the results are comparable with infliximab and its biosimilars (20).

In studies on drug monitoring in PIBD, the grouping of the patients according to their therapeutic response is most often based on clinical remission, defined with PCDAI or PUCAI indices (25, 30). In the study by van Hove et al. (27), 40 patients underwent endoscopy after a median of 12.6 months

and there were in total 87 time points for endoscopic data. In 54% of the visits, the patients were in endoscopic remission. In those children who were in remission, the median infliximab trough levels were significantly higher compared to those not in remission (**Table 1**).

In clinical practice, most have measured trough levels when the therapeutic response is not optimal or there has occurred an adverse event that might be related to the presence of drug antibodies and low trough levels. Although drug antibody formation is rare during first weeks of therapy (18, 37), there has been discussion whether trough levels should be measured already during induction. Suboptimal trough levels may guide therapy enhancement and in theory, adjusting the dosing early may prevent loss of response. If trough levels are suboptimal at week 6 to 8, this may associate with inferior therapeutic response (10, 38) and increase the risk for antibody formation prior the first maintenance dose (fourth dose of the therapy). To avoid this, many clinics have started to monitor the trough level for the first time at week 6 to be able to enhance the therapy in due course when needed. Indeed, higher trough levels at the first dose of maintenance predicted sustained remission at 1 year (26). Recently, it was suggested that infliximab concentration of $\geq 29 \mu\text{g/ml}$ at infusion 2 and $\geq 18 \mu\text{g/ml}$ at infusion 3 was associated with improved outcomes (25) in infliximab-treated patients with PIBD.

When decisions on drug dosing are based on clinical data, inflammatory markers and drug levels, most pediatric patients need therapy adjustment compared to standard of care (39). One of the first studies reporting comparison of patients with PIBD followed up with proactive drug level monitoring and patients with standard care, concluded that there was a difference in the median values of the drug levels between these groups but no difference in the therapeutic outcomes (24). Thus, although in the current practice most aim to achieve higher trough levels to improve therapeutic response and to diminish loss of efficacy, the data on showing that this indeed results in better outcomes are sparse.

The mechanisms for the loss of response to infliximab therapy are not completely understood. Several hypotheses have been proposed including e.g., (1) drug antibody formation (2) a high inflammatory load of the disease and rapid turnover of the drug (3) development of an alternate inflammatory pathway. To avoid drug antibody formation, some favor combination therapy with immunosuppressants although this increases the risk of severe adverse events (40) and does not invariably protect from drug antibody formation (19). In young children, the clearance of infliximab has been estimated to be more rapid and to achieve target levels of the drug, higher doses around 10 mg/kg and shortening of the interval to 4–5 weeks may be needed (41). A recent study summarized data from 215 patients with PIBD treated with infliximab and with trough level measurements during induction and maintenance. Regarding patients younger than 10 years of age, two thirds of the patients had trough levels below the target level at the start of the maintenance therapy. After one year of therapy, the dose requirements and risk to develop drug antibodies were higher in the group of young patients compared to the older

TABLE 1 | Summary of the main studies included in the review.

References	No. of patients	Age years	Trough level measurements	Drug antibody measurements	Results from trough level measurements
Naviglio et al. (23)	49 Crohn 34 UC 15	14 median (IQR 11.6-16.2)	<i>n</i> = not available at week 6,14,22,54	When IFX level <1.5 mg/mL 10 patients (20.4%) had low levels and were positive for drug antibodies	at week 6 In clinical remission median 9.8 μg/mL (IQR 8.4 to 12.6) vs. 7.1 μg/mL (IQR 4.7 to 9.8 μg/mL) in active disease at week 54 In clinical remission median 6.1 μg/mL (IQR 3.8-9.6) vs. 1.4 μg/mL (IQR 0.35-2.8 μg/mL) in active disease
Lega et al. (24)	83 Crohn 76 UC 7	14 Median (IQR 11-16)	<i>n</i> = 243 during maintenance	25 (30%) positive for drug antibodies	In proactive monitoring group median 9.1 μg/mL (IQR 6.2-13) vs. 5.4 μg/mL (IQR 1.7-10.8) in the group of standard care
Clarkston et al. (25)	72	13 mean (SD±4)	<i>n</i> = not available during induction	None	In clinical responders median 27.8 μg/mL (IQR19.5– 40) at infusion 2 and 14 μg/ml (IQR 8.3–24) at infusion 3
van Hoeve et al. (26)	35 Crohn 23 UC 12	12.7 (IQR 10.2–14.6)	<i>n</i> = 35 at week 12 to 14	In 3 with undetectable trough levels but all negative	Clinical 4.6mg/mL (IQR2.7) vs. 1.5 mg/mL (IQR 0.9–3.0), biological 4.6 mg/mL (IQR 2.5–10.3) vs. 2.6 mg/mL (IQR 0.3–3.2) and combined clinical/biological remission 6.0mg/mL (IQR 3.2–12.0) vs. 2.6mg/mL (IQR 1.1–3.2) at week 52 compared to children not meeting these criteria (all <i>P</i> < 0.002)
van Hoeve et al. (27)	52 Crohn 33 UC 19		<i>n</i> = 686 during maintenance		In clinical, biological and endoscopic remission median levels were 5.2, 5.7 and 6.5 μg/mL, respectively, and higher than in those not meeting these criteria 4.2 μg/mL (IQR 2.6-6.7) 3.7 mg/L (IQR 1.8-5.4) and 1.2 mg/L (IQR 0.03-4.4; <i>P</i> = 0.01), respectively
Ungar et al. (28)	63 Crohn 50 UC 13	median 14 (IQR 11.75-16)	<i>n</i> = 773 during induction and maintenance (<i>n</i> = 682)	At week 6 and 14 median levels of drug antibodies higher in patients discontinuing the therapy during 1 year vs. patients with ongoing therapy	In clinical remission 4.0 mg/mL (IQR 2.0–6.4) vs. 2.25 mg/mL (IQR 0.5–4.7; <i>p</i> <0.0001) in clinically active disease Median levels at week 2 higher when in clinical remission at week 14: 12.8 mg/mL (IQR 9.7–16.2) in clinical remission compared to 7.6 mg/mL (IQR 2.1–12.9) in clinically active disease (<i>P</i> < 0.02) Median levels at week 6 higher when in clinical remission at week 14: 8.4 mg/mL, (IQR 6.9–17.0) in clinical remission vs. 5.5 mg/mL (IQR 0.27–12.3) in clinically active disease (<i>P</i> < 0.04)
Merras-Salmio and Kolho (19)	145 Crohn 101 UC 32 IBDU 12	14.8 median (IQR 12.5–16.0)	<i>n</i> = 475 during induction and maintenance	208 analyses when IFX <2.0 mg/L, 65% positive when IFX <0.2 mg/L, 89% positive	In remission and/or ongoing therapy median 3.7 mg/L (IQR 1.8-5.4) vs. 1.2 mg/L (IQR 0.05-4.4) in the group with loss of efficacy or no efficacy
Choi et al. (29)	39 Crohn 29 UC 10	< 19	<i>n</i> = 99 during maintenance	Drug antibodies 0/16 with good response and 7/23 with poor response	In clinical remission levels higher than in those with poor response median 3.99 μg/mL (IQR, 0.30-21.96) vs. 0.88 μg/mL (IQR, 0.00-6.80, <i>p</i> =0.002)
Rolandsdotter. (30)	45 Crohn 32 UC 13	7-18	<i>n</i> = 93 during maintenance	12 samples with undetectable trough levels and all positive for drug antibodies	In clinical remission mean levels higher (7.2 μg/mL) compared to active disease 4.5 μg/mL (<i>p</i> < 0.05)
Deora et al. (31)	73 Crohn 52 UC 18 IBDU 3	median 16.12 (IQR 14.34-17.91)	<i>n</i> = 107 during maintenance	None	In UC median 4.2 μg/mL (IQR = 2.4–9.477) and in Crohn 5.9 (IQR = 3.9–12.65) in suboptimal response (<i>n</i> = 38; 35.5%) median 1.8 μg/mL (range 0.04–3.4)

IBDU, unclassified inflammatory bowel disease; IQR, interquartile range; UC, ulcerative colitis.

patient group (41). The therapeutic outcome in the young patients, however, was not different from the older patients (24, 41). However, it is not just weight or age of the patients that have an impact on the trough levels and the outcome

of the therapy. The level of inflammation as reflected in the levels of albumin and inflammatory markers is a key player in drug pharmacokinetics (42). Therefore, in patients with high inflammatory load, higher dosing of infliximab is needed to reach

target levels (3, 5). Disappointingly, a recent report stated that although trough levels during induction therapy with infliximab increased and antibody formation decreased, the proportion of pediatric patients maintaining their therapeutic response during the first year did not increase (20). It is not clear why some patients with trough levels considered as adequate, lose their therapeutic response. As this may occur after several months of maintenance therapy, it has been suggested that in these late non-responders the inflammatory pathway is altered and becomes resistant to TNF α blockade (43, 44). Indeed, the initial response to infliximab therapy during induction is predictive for the long-term outcome of the therapy both in children and in adults with IBD. Patients with low levels of fecal calprotectin at the end of induction are more likely to have a favorable long-term outcome compared to patients with elevated levels of fecal calprotectin reflecting ongoing inflammation after induction (7, 45).

Is Determination of Drug Antibodies Necessary?

There are several different tests for the detection of drug antibodies, each having different levels of detection and cut-offs for a raised value. In most assays, the level of infliximab interferes with the test performance and the result is negative when there is measurable infliximab in the blood (32). When drug levels are undetectable, the risk of antibody formation is increased and thus, a rapid therapy escalation is needed. In clinical practice, this most often includes shortening of the interval and increasing the dose (e.g., (10, 41)). However, when trough levels of the drug are well within the target range, the impact of measurable drug antibodies is less likely to be of clinical importance. Notably, drug antibodies may appear already during induction (18, 46) although in most cases they are detected during maintenance at the time of secondary loss of response (32). In the single-center report by Cohen and co-authors, drug antibodies with a detection limit of 3.1 U/mL for infliximab were present in one fourth of the anti-TNF α treated patients (47). They concluded that therapy optimization rather than switching to another therapeutic agent is advisable with antibody level < 10 U/mL. In several reports, it has been suggested that high antibody titers carry a risk for antibody-related adverse events, e.g., serum sickness type antigen-antibody reaction, but the definition of such a high level of antibodies is inconclusive. The pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in PIBD was recently comprehensively reviewed (12). Taken together, there is no need

to measure drug antibodies when trough levels are within the therapeutic range but when trough levels are undetectable, drug antibody measurement is recommended and if the antibody titer is exceedingly high, it is advisable to discontinue the drug therapy.

CONCLUSIONS

Therapeutic drug monitoring of infliximab is here to stay for clinical decision-making. Patient age, weight and severity of the disease are important contributors to be taken into consideration when adjusting the therapy. Currently, trough levels above 3–5 mg/mL are considered adequate but in fistulizing disease target levels may be higher (~10 mg/mL or more). An active infliximab trough monitoring strategy should be implemented with automatic measurement of drug antibodies in low trough levels. With such practice, patients with incomplete therapeutic response will have timely escalation of the therapy and possibly less drug antibody formation. When trough levels are within the target range, the determination of drug antibodies does not have clinical significance. With low trough levels and detectable drug antibodies, therapy enhancement may result in disappearance of the drug antibodies. However, with high titers of drug antibodies (the absolute values depending on the assay used), there is a risk for adverse antigen-antibody reactions and therapy should be discontinued at physician's discretion. When efficacy is not sufficient and trough levels are high, such patients are candidates for switching to another therapeutic agent. It seems that proactive therapeutic drug monitoring does not remarkably increase the proportion of patients having a long-term response to infliximab therapy but it aids in the recognition of the drug non-responders and therefore has the potential to result in a more cost-effective therapy.

AUTHOR CONTRIBUTIONS

K-LK conceptualization, interpretation of data, and writing original draft.

FUNDING

Pediatric Research Foundation (Finland) and Helsinki University Hospital Research Fund have provided study support for an ongoing research project on pediatric inflammatory bowel disease.

REFERENCES

- Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. *Int J Mol Sci.* (2019) 20:2529. doi: 10.3390/ijms20102529
- de Ridder L, Assa A, Bronsky J, Romano C, Russell RK, Afzal NA, et al. Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the pediatric IBD porto group of eSPGHAN. *J Pediatr Gastroenterol Nutr.* (2019) 68:144–153. doi: 10.1097/MPG.00000000000002141
- van Rheenen PF, Aloï M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric crohn's disease: an ECCO-ESPGHAN guideline update. *J Crohns Colitis.* (2020). doi: 10.1093/ecco-jcc/jjaa161. [Epub ahead of print].
- Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based guideline from european crohn's and colitis organization and european society of paediatric gastroenterology, hepatology and nutrition. *J Pediatr Gastroenterol Nutr.* (2018) 67:257–91. doi: 10.1097/MPG.0000000000002035

5. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis—an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr.* (2018) 67:292–310. doi: 10.1097/MPG.0000000000002036
6. De Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM, Kneepkens CM, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. *Aliment Pharmacol Ther.* (2011) 33:243–50. doi: 10.1111/j.1365-2036.2010.04507.x
7. Kolho KL, Sipponen T. The long-term outcome of anti-tumor necrosis factor- α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. *Scand J Gastroenterol.* (2014) 49:434–41. doi: 10.3109/00365521.2014.886719
8. Topf-Olivestone C, Turner D. How effective is the use of long-term anti-TNF for paediatric IBD? Clues from real-life surveillance cohorts. *Arch Dis Child.* (2015) 100:391–2. doi: 10.1136/archdischild-2014-306467
9. Vande Castele N, Ferrante M, Van Assche G, Ballet V, Compernelle G, Van Steen K et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. *Gastroenterology.* (2015) 148:1320–9.e3. doi: 10.1053/j.gastro.2015.02.031
10. Jooose ME, Samsom JN, van der Woude CJ, Escher JC, van Gelder T. The role of therapeutic drug monitoring of anti-Tumor necrosis factor alpha agents in children and adolescents with inflammatory bowel disease. *Inflamm Bowel Dis.* (2015) 21:2214–21. doi: 10.1097/MIB.0000000000000420
11. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Castele N, Kozuch PL, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol.* (2019) 17:1655–68.e3. doi: 10.1016/j.cgh.2019.03.037
12. Winter DA, Jooose ME, de Wildt SN, Taminiau J, de Ridder L, Escher JC. Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations. *J Pediatr Gastroenterol Nutr.* (2020) 70:763–76. doi: 10.1097/MPG.0000000000002631
13. Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. *Scand J Gastroenterol.* (2015) 50:74–80. doi: 10.3109/00365521.2014.987809
14. Colman RJ, Tsai YT, Jackson K, Boyle BM, Noe JD, Hyams JS, et al. Achieving target infliximab drug concentrations improves blood and fecal neutrophil biomarkers in Crohn's disease. *Inflamm Bowel Dis.* (2020). doi: 10.1093/ibd/izaa241. [Epub ahead of print].
15. Haas L, Chevalier R, Major BT, Enders F, Kumar S, Tung J. Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease. *Dig Dis Sci.* (2017) 62:3110–6. doi: 10.1007/s10620-017-4745-1
16. Lepp J, Höög C, Forsell A, Fyrhake U, Lördal M, Almer S. Rapid weight gain in infliximab treated Crohn's disease patients is sustained over time: real-life data over 12 months. *Scand J Gastroenterol.* (2020) 55:1411–18. doi: 10.1080/00365521.2020.1837929
17. Hämäläinen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. *World J Gastroenterol.* (2011) 17:5166–71. doi: 10.3748/wjg.v17.i47.5166
18. Hämäläinen A, Sipponen T, Kolho KL. Serum infliximab concentrations in pediatric inflammatory bowel disease. *Scand J Gastroenterol.* (2013) 48:35–41. doi: 10.3109/00365521.2012.741619
19. Merras-Salmio L, Kolho KL. Clinical use of infliximab trough levels and antibodies to infliximab in pediatric patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* (2017) 64:272–8. doi: 10.1097/MPG.0000000000001258
20. Nikkonen A, Kolho KL. Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease. *Acta Paediatr.* (2020) 109:836–41. doi: 10.1111/apa.15026
21. Guidi L, Pugliese D, Tonucci TP, Berrino A, Tolusso B, Basile M, et al. Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multicentre study. *J Crohns Colitis.* (2018) 12:1079–88. doi: 10.1093/ecco-jcc/jjy076
22. Wren AA, Park KT. Targeted dosing as a precision health approach to pharmacotherapy in children with inflammatory bowel disease. *AMA J Ethics.* (2018) 20:E841–8. doi: 10.1001/amajethics.2018.841
23. Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, et al. Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study. *J Pediatr Gastroenterol Nutr.* (2019) 68:37–44. doi: 10.1097/MPG.0000000000002112
24. Lega S, Phan BL, Rosenthal CJ, Gordon J, Haddad N, Pittman N, et al. Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD. *Inflamm Bowel Dis.* (2019) 25:134–41. doi: 10.1093/ibd/izy203
25. Clarkston K, Tsai YT, Jackson K, Rosen MJ, Denson LA, Minar P. Development of infliximab target concentrations during induction in pediatric Crohn disease patients. *J Pediatr Gastroenterol Nutr.* (2019) 69:68–74. doi: 10.1097/MPG.0000000000002304
26. van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, et al. Adequate infliximab exposure during induction predicts remission in paediatric patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* (2019) 68:847–53. doi: 10.1097/MPG.0000000000002265
27. van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, et al. Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease. *J Crohns Colitis.* (2018) 12:1316–25. doi: 10.1093/ecco-jcc/jjy111
28. Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, et al. Association between infliximab drug and antibody levels and therapy outcome in pediatric inflammatory bowel diseases. *J Pediatr Gastroenterol Nutr.* (2018) 67:507–12. doi: 10.1097/MPG.0000000000002051
29. Choi SY, Kang B, Choe YH. Serum infliximab cutoff trough level values for maintaining hematological remission in pediatric inflammatory bowel disease. *Gut Liver.* (2019) 13:541–8. doi: 10.5009/gnl18129
30. Rolandsdotter H, Marits P, Sundin U, Wikström AC, Fagerberg UL, Finkel Y, et al. Serum-Infliximab trough levels in 45 children with inflammatory bowel disease on maintenance treatment. *Int J Mol Sci.* (2017) 18:575. doi: 10.3390/ijms18030575
31. Deora V, Kozak J, El-Kalla M, Huynh HQ, El-Matary W. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease. *Acta Paediatr.* (2017) 106:1863–7. doi: 10.1111/apa.14008
32. Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF- α levels in inflammatory bowel disease. *Aliment Pharmacol Ther.* (2012) 35:971–86. doi: 10.1111/j.1365-2036.2012.05057.x
33. Hofmekler T, Bertha M, McCracken C, Martineau B, McKinnon E, Schoen BT, et al. Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* (2017) 64:580–5. doi: 10.1097/MPG.0000000000001302
34. El-Matary W, Walters TD, Huynh HQ, deBruyn J, Mack DR, Jacobson K, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn's disease in children. *Inflamm Bowel Dis.* (2019) 25:150–5. doi: 10.1093/ibd/izy217
35. Greener T, Kabakchiev B, Steinhart AH, Silverberg MS. Higher infliximab levels are not associated with an increase in adverse events in inflammatory bowel disease. *Inflamm Bowel Dis.* (2018) 24:1808–14. doi: 10.1093/ibd/izy066
36. Papamichail K, Clarke WT, Castele NV, Germansky KA, Feuerstein JD, Melmed GY, et al. Comparison of assays for therapeutic monitoring of infliximab and adalimumab in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol.* (2020). doi: 10.1016/j.cgh.2020.03.002. [Epub ahead of print].
37. Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. *Gut.* (2014) 63:1258–64. doi: 10.1136/gutjnl-2013-305259
38. Adedokun OJ, Xu Z, Padgett L, Blank M, Johanns J, Griffiths A, et al. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. *Inflamm Bowel Dis.* (2013) 19:2753–62. doi: 10.1097/01.MIB.0000435438.84365.f7
39. Dubinsky MC, Phan BL, Singh N, Rabizadeh S, Mould DR. Pharmacokinetic dashboard-Recommended dosing is different than standard of care dosing in infliximab-Treated pediatric IBD patients. *AAPS J.* (2017) 19:215–22. doi: 10.1208/s12248-016-9994-y

40. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. *Gastroenterology*. (2018) 155:337–46.e10. doi: 10.1053/j.gastro.2018.04.012
41. Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho KL, et al. Infliximab in young paediatric iBD patients: it is all about the dosing. *Eur J Pediatr*. (2020) 179:1935–44. doi: 10.1007/s00431-020-03750-0
42. Bauman LE, Xiong Y, Mizuno T, Minar P, Fukuda T, Dong M, et al. Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease. *Inflamm Bowel Dis*. (2020) 26:429–39. doi: 10.1093/ibd/izz143
43. Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. *Immunotherapy*. (2015) 7:175–90. doi: 10.2217/imt.14.105
44. Roblin X, Vérot C, Paul S, Duru G, Williet N, Boschetti G, et al. Is the pharmacokinetic profile of a first anti-TNF predictive of the clinical outcome and pharmacokinetics of a second anti-TNF? *Inflamm Bowel Dis*. (2018) 24:2078–85. doi: 10.1093/ibd/izy111
45. Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF α blocking agents. *Inflamm Bowel Dis*. (2012) 18:2011–7. doi: 10.1002/ibd.22863
46. Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, et al. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. *Aliment Pharmacol Ther*. (2018) 47:212–8. doi: 10.1111/apt.14410
47. Cohen RZ, Schoen BT, Kugathasan S, Sauer CG. Management of anti-drug antibodies to biologic medications in children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. (2019) 69:551–6. doi: 10.1097/MPG.0000000000002440

Conflict of Interest: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Kolho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.